Tau | search
Click here to view Tau news from 60+ newspapers.
Bookmark or Share- Tau: Why Alzheimer’s Worsens Fast in Some, Slowly in OthersPhosphorylation of specific tau residues associated with rate of decline. “This is a well-designed study underlining once more the importance of the soluble tau oligomeric assemblies over long tau filaments in Alzheimer’s disease, as well as heterogeneity in tau oligomers,” commented Rakez Kayed of the University of Texas Medical Branch ...
- E2814 | ALZFORUMThe trial’s primary endpoint is tau spread during E2814 treatment, measured by tau PET in the symptomatic cohort. Secondary outcomes in this group include change in a cognitive composite, amyloid PET, and CSF neurofilament light chain. In the asymptomatic population, change in CSF ptau217/total tau ratio is the outcome.
- Where to Now, Phospho-Tau? - ALZFORUMPlasma p-tau181 and p-tau217 values of 1.56 pg/mL and 0.25 pg/mL, respectively, or greater, predicted amyloid-positivity with specificities of 92 percent and 96 percent, respectively. Alas, sensitivities were low, around 50 percent, meaning the algorithm missed half of the people who did have brain amyloid.
- Tau (MC-1) - ALZFORUMMC-1 stains neurons in the brains of transgenic mice expressing aggregation-prone human tau. A) Section through the hippocampus of a mouse expressing human tau with the ΔK280 mutation that promotes tau aggregation. B) MC-1 immunoreactivity is absent from the brains of transgenic mice expressing human tau with the ΔK280 mutation and two ...
- Tau Modification Drugs Take a Hit with Negative Trial14 Nov 2024. While anti-tau antibodies are beginning to look promising (see previous story), small molecules that modify tau proteins haven’t yet fared well in clinical trials. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 3 in Madrid, Eli Lilly’s negative trial was a setback for ceperognastat ...
More
